- Home
- AKA vs INBX Comparison
AKA vs INBX Comparison
Compare AKA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- INBX
- Stock Information
- Founded
- AKA 2018
- INBX 2010
- Country
- AKA United States
- INBX United States
- Employees
- AKA N/A
- INBX N/A
- Industry
- AKA Catalog/Specialty Distribution
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- INBX Health Care
- Exchange
- AKA Nasdaq
- INBX Nasdaq
- Market Cap
- AKA 110.4M
- INBX 345.8M
- IPO Year
- AKA 2021
- INBX 2020
- Fundamental
- Price
- AKA $10.56
- INBX $26.54
- Analyst Decision
- AKA Strong Buy
- INBX Hold
- Analyst Count
- AKA 3
- INBX 2
- Target Price
- AKA $24.33
- INBX N/A
- AVG Volume (30 Days)
- AKA 4.4K
- INBX 112.9K
- Earning Date
- AKA 11-06-2025
- INBX 11-13-2025
- Dividend Yield
- AKA N/A
- INBX N/A
- EPS Growth
- AKA N/A
- INBX N/A
- EPS
- AKA N/A
- INBX N/A
- Revenue
- AKA $598,107,000.00
- INBX $1,400,000.00
- Revenue This Year
- AKA $7.29
- INBX N/A
- Revenue Next Year
- AKA $4.10
- INBX N/A
- P/E Ratio
- AKA N/A
- INBX N/A
- Revenue Growth
- AKA 7.67
- INBX N/A
- 52 Week Low
- AKA $7.00
- INBX $10.81
- 52 Week High
- AKA $29.20
- INBX $30.23
- Technical
- Relative Strength Index (RSI)
- AKA 46.35
- INBX 52.65
- Support Level
- AKA $10.37
- INBX $27.51
- Resistance Level
- AKA $10.93
- INBX $28.86
- Average True Range (ATR)
- AKA 0.40
- INBX 1.38
- MACD
- AKA 0.01
- INBX -0.37
- Stochastic Oscillator
- AKA 41.04
- INBX 8.54
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.